FMEV retroviral vectors combine the long terminal repeat fluorescent protein and truncated low affinity nerve growth of Friend mink cell focus-forming viruses with the 5′ factor receptor), we formally demonstrate that both the long untranslated leader region of the murine embryonic stem terminal repeat and the leader contribute to the high cells virus. These modules were connected to achieve high expression of FMEV in transduced hematopoietic cells. transgene expression in hematopoietic progenitor and Most prominent are the data recorded in the absence of stem cells. Here, we report the cloning of safety-improved selection in myelo-erythroid progenitor cells. Here, FMEV and versatile FMEV vectors allowing module-wise vectors mediate up to two orders of magnitude increased exchange of crucial elements for comparative studies. By transgene expression levels when compared with vectors transfer and expression of four different marker genes based on the Moloney murine leukemia virus. (neomycin phosphotransferase, lacZ, enhanced green
FMEV retroviral vectors combine the long terminal repeat fluorescent protein and truncated low affinity nerve growth of Friend mink cell focus-forming viruses with the 5′ factor receptor), we formally demonstrate that both the long untranslated leader region of the murine embryonic stem terminal repeat and the leader contribute to the high cells virus. These modules were connected to achieve high expression of FMEV in transduced hematopoietic cells. transgene expression in hematopoietic progenitor and Most prominent are the data recorded in the absence of stem cells. Here, we report the cloning of safety-improved selection in myelo-erythroid progenitor cells. Here, FMEV and versatile FMEV vectors allowing module-wise vectors mediate up to two orders of magnitude increased exchange of crucial elements for comparative studies. By transgene expression levels when compared with vectors transfer and expression of four different marker genes based on the Moloney murine leukemia virus. (neomycin phosphotransferase, lacZ, enhanced green Keywords: retroviral vectors; hematopoietic cells; transcriptional control FMEV is a retroviral vector which combines the enhancer and promoter derived from the long terminal repeat (LTR) of Friend mink cell focus-forming viruses (FMCF) such as polycythemic spleen focus-forming virus (SFFVp) with the 5′ untranslated leader of the murine embryonic stem cell virus (MESV). While the enhancer/promoter of SFFVp mediates powerful initiation of transcription in both multipotent and lineage-restricted progenitor cells, 1,2 the MESV leader was included to avoid transcriptional repression by the repressor binding site overlapping the primer binding site (PBS). 1, 3 FMEV leads to high and constitutive transgene expression in hematopoietic cells and thus represents a valuable tool for many applications in gene therapy. Examples are transfer and expression of drug-resistance genes to mediate dominant selection in vivo, gene marking using cell surface antigens or cytoplasmic markers, correction of lysosomal storage disorders or other inherited metabolic diseases with myeloid cells and finally inhibition of viral infections by intracellular immunization. 4 Recent data showed that FMEV also exhibits high activity in human T-and B-lymphocytes (Zaehres and Baum, unpublished data), further widening the potential clinical utility of FMEV. In the present report, we describe a novel generation of FMEV vectors. These are used to demonstrate formally that both the LTR and the leader contribute to the excellent performance of FMEV in hematopoietic cells.
The basic FMEV plasmid pSF1 ( Figure 1 ) was designed to fulfil current safety criteria of retroviral vector constructs, and allows modular exchange of crucial retroviral control elements. pSF1 differs from the backbone of the prototype FMEV, SF-MDR: 1 it contains the env-deleted 3′ untranslated region from the LX series developed by Miller. 5, 6 Furthermore, two different versions of small, but versatile polylinkers were introduced, and the SFFVp-LTR was engineered to enable exchange of enhancer/promoter sequences using restriction sites NheI and KpnI (Figure 1a) . The resulting two basic vectors were sequenced and the data submitted to the GenBank database (see legend to Figure 1 for accession numbers). In the present study, pSF1 was used to create vectors with defined exchanges of crucial control elements, but which are otherwise completely identical (Figure 1b ). This enabled a precise comparative analysis of the importance of the LTR and leader sequences for marker gene expression.
Sequence comparison of the FMEV leader with the corresponding region of LX vectors, which have been developed for safe and high-titre packaging on the basis of Moloney murine leukemia virus (MoMLV) and of Moloney murine sarcoma virus (MoMSV), showed 80% overall sequence conservation upstream of the residual gag sequences (Figure 1) . 5, 7, 8 9 The first 80 bp of the core packaging region () between MscI (bp 216) and XmaIII (bp 355) contain a stretch of remarkably low sequence conservation (less than 50%). 8 Leader sequences 
from plasmid R250-MESV-Dlngfr-Sa-Mneo using primers kdelta+NotI (5′-GCGGCCGCATGGGGGCAGGTGCCACCGGCC-3′) and U3-(5′-CGCGCGAACAGAAGCGAGAAG-3′). The EGFP cDNA contained in SF1␥, MO1␥ and MO3␥ was amplified with Pfu-polymerase from plasmid pEGFP-C1 (Clontech) using primers EGFP+NotI (5′-GCGGCCGCCATGGTGAGCAAGGGCGAGGAGCTGTTC-3′) and EGFP-Xho1 (5′-CTCGAGTTATCGAGATCTGAGTCCGGACTTGTAC-3′).
downstream of PstI (bp 574) are identical in FMEV and LX vectors. They contain the first 418 bp of the gag coding region, which has been preserved for optimal packaging. 7, 10 To prevent translation in the gag frame, the former AUG of gag was mutated to a stop codon (TAG, bp 627), as in LX vectors. 5 To address whether the differences in the leader or in the LTR influence packaging, we compared the titers of monocistronic vectors transducing the neomycin phosphotransferase II (neoR) cDNA, and thus conferring resistance to geneticine (G418). We used vectors with identical architecture, except for defined exchanges in the leader or in the LTR (Figure 1b) . Mass cultures of GP& envAM12 producer cells releasing replication-incompetent amphotropic vectors were established under identical conditions by retroviral transduction from transfected ecotropic producer cells GP&env86. Upon limiting dilution of cell-free tissue culture supernatants, the amphotropic neoR-vectors MO3N (LX-type, ie MoMLV-LTR and MoMSV-leader), MO1N (MoMLV-LTR, MESV-leader) and SF1N (FMEV) gave similar titers on murine fibroblasts GP&env86. Titers of uncloned producers were in the range of 2-5 × 10 5 G418 resistance transducing units (GTU) per ml supernatant. Irrespective of the vector backbone, we routinely obtained producer clones releasing up to 5 × 10 6 GTU/ml from screening 12 independent clones. Thus, neither the SFFVp-LTR nor the MESV leader have profound effects on retroviral titers. The titration on fibroblasts was not influenced by the different enhancer elements, because expression levels in fibroblasts were almost equivalent (see below).
We next dissected the importance of the enhancer/ promoter and leader modules of FMEV for vector expression. Various cell lines representing distinct stages of hematopoiesis, 1, 11 were transduced with the neoR vectors SF1N, MO1N and MO3N, as well as with the corresponding vectors SF1L, MO1L and MO3L, containing a fused lacZ-neoR (leoR) marker gene (Figure 1b) . We previously showed by transient transfection assays that the enhancer/promoter of SFFVp is up to one order of mag-nitude more active than that of MoMLV, and that the use of the PBS of MESV avoids transcriptional repression of the LTR. 1 The importance of each of these modules has not been dissected previously by retroviral gene transfer. We now observed that the MESV leader elevated relative transduction efficiencies in hematopoietic cells (MO1N versus. MO3N). SF1N with the SFFVp-LTR and the MESV leader gave even higher transduction levels (Figure 2a) .
The leoR marker permits linear quantification of vector expression in bulk preparations of cytoplasmic extracts. It became apparent that the MoMLV/MoMSV-based vector, MO3L, is about one order of magnitude less active than the corresponding FMEV, SF1L, in myelo-erythroid cells (Figure 2b ). In line with data obtained by transient transfection, 1 the MESV-leader (MO1L) was clearly superior to the MoMSV-leader (MO3L). The strongest difference was observed in the most primitive hematopoietic cells, FDCP-mix (the cell line is further described in Refs 1 and 11). This may indicate that the repressing function may be stronger in more primitive hematopoietic cells. Alternatively, the repressor may act constitutively, and therefore becomes more important or dominant when LTR function is reduced, as in more primitive hematopoietic and embryonic cells. In contrast to hematopoietic cells, only marginal leader-dependent repression was observed in fibroblasts SC1, and in these cells no further enhancement of expression was achieved with the LTR of SFFVp (Figure 2b) .
The LTR of SFFVp was always more active than that of MoMLV in all myelo-erythroid cells analyzed, with the strongest enhancement (more than five-fold) in K562 cells. The LTR-dependent differences detected with leoR were, however, not as marked as those measured using transient transfection or retroviral transduction of the human multidrug resistance 1 gene. 1, 11 This may be due to a bias of the G418 selection, as evident from experiments shown above (Figure 2a) . Therefore, we employed two other markers allowing comparison of vector expression at the single cell level and without selection. These were the cytoplasmic marker enhanced green fluorescent protein (EGFP, or simply ␥ in our vector nomenclature), 12 and the cell surface marker, low affinity nerve growth factor receptor lacking the cytoplasmic signal transduction domain (⌬LNGFR, or simply ␦).
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Expression of these genes allows preparative sorting of transduced cells by flow cytometry (EGFP) 14 or, which may be of greater utility for clinical settings, also by immunoaffinity (⌬LNGFR). 13 However, potential drawbacks such as immunogenicity (EGFP) or interference with signalling pathways (⌬LNGFR) still remain to be elucidated. 15 In the present study, we preferentially addressed the utility of these genes as reporters for vector expression. Vector architectures were similar to those used for transfer of neoR or leoR (Figure 1b) .
Both with ⌬LNGFR and EGFP, the expression levels were strictly dependent on the control elements of the retroviral vectors. Our MoMLV/MoMSV-based EGFPvector, MO3␥, mediated poor expression in K562 cells, with incomplete separation of transduced K562 cells from untransduced controls in flow cytometry. The MESV leader (vector MO1␥) improved expression from the MoMLV-LTR. However, clear separation of transduced cells from untransduced control required the stronger LTR of the FMEV construct, SF1␥ (Figure 3a ). An excellent sensitivity of marker gene expression was obtained with ⌬LNGFR in flow cytometry (Figure 3b-e) . Markedly increased expression was noted from an MoMLV-driven vector when combined with the permissive leader of MESV in hematopoietic cells (Figure 3b) . The strong LTR of the FMEV, SF1␦ further enhanced surface marker expression (four-fold increase in mean fluorescence), resulting in a dramatic shift of fluorescence intensity over untransduced cells (Figure 3c ). To demonstrate that FMEV also mediate enhanced expression of cell surface markers in primary human hematopoietic cells, high-titer producers were established for SF1␦ and MO3␦ and serum-free supernatants were used to transduce CD34 cells using a very efficient novel protocol. 16 Compared with MO3␦, SF1␦ mediated strikingly increased expression of ⌬LNGFR in CD34 + cells (Figure 3d ). Equivalent data were obtained in CD34 − subsets of primary cells (not shown). In contrast to hematopoietic cells, fibroblasts showed a less prominent effect of the MESV leader, while the inclusion of the SFFVp-LTR had no positive effect in these cells (Figure 3e ). Very similar data were obtained using retroviral vectors with the leoR marker (Figure 2b) , and also by transient transfection. 1 Both EGFP and ⌬LNGFR allowed us to obtain data without any bias by previous selection of transduced cells. Taken together, our results clearly demonstrate that FMEV-based vectors mediate up to two orders of magnitude higher transgene expression in myelo-erythroid progenitor cells, including primary CD34 + cells, than vectors completely relying on MoMLV-related control elements. This highly significant increase was specific for hematopoietic cells and achieved with the combination of the powerful LTR of the FMCF-related virus, SFFVp, with the permissive leader of MESV. Other vector components (elements controlling translation efficiency or RNA stability and polylinker sequences) were not responsible for the observed differences, because the sequences outside the LTR or the leader were absolutely identical in this study. Thus, this study for the first time formally demonstrates that leader-mediated repression of retroviral activity occurs in human cells, and that this repression can be overcome with the MESV leader. An interesting additional observation was that the MoMLV-LTR could be rescued to considerable activity when combined with the MESV leader.
We conclude that MoMLV/MoMSV-type vectors may be sufficient for purposes requiring only modest transcription, but MoMLV/MESV-hybrid vectors or, even better, FMEV are superior when stronger transgene expression is necessary. Even absolute advantages for FMEV can be seen in conditions requiring a strong expression above background levels, and when a strong selective pressure is applied. FMEV vectors may thus be a prerequisite for successful application of retroviral gene transfer in certain experimental and clinical settings. 11, 17 The FMEV basic vectors described here contain versatile restriction sites that allow insertion of transgenes and module-wise analysis of cassettes used for vector design. These vectors are currently used to study the importance of individual responsive elements of the SFFVpenhancer, 2 and to analyze ways to improve transgene translation (see also Ref. 18) . Hopefully, these vectors will become valuable for further work in experimental hematology and gene therapy.
